UNITED THERAPEUTICS Corp 4

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics (UTHR), exercised 9,500 stock options at $135.42 and sold approximately 8,262 shares of common stock (directly and via a family trust) on July 15, 2026 for about $4.4 million under a 10b5-1 trading plan.

On July 15, 2026, United Therapeutics Corporation Chairperson & CEO Martine A. Rothblatt exercised two tranches of stock options for a total of 9,500 shares of common stock at a strike price of $135.42 per share (1,718 shares into her direct account and 7,782 shares into a family trust), then sold essentially all of the resulting shares the same day in a series of open-market transactions under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. In her direct account she exercised 1,718 options, increasing her directly held common stock to 42,231 shares, and then sold 1,120 shares in multiple trades at prices ranging from approximately $521.82 to $534.09, leaving 40,513 shares held directly. In a family trust, she exercised 7,782 options (with the related 7,782 shares reported as indirectly owned by trust at an indicated value of $341,410, which is the intrinsic value, not the market value), and then the trust sold 7,142 shares in numerous trades at weighted-average prices around $521–$534, reducing that trust’s holdings from 332,225 to 324,443 shares. Across all sales, she disposed of roughly 8,262 shares at average prices near $528 per share, for an estimated gross sale value of about $4.4 million versus an aggregate exercise cost of about $1.29 million, with the Form 4 specifying that the sales are part of a continuing 10b5-1 plan covering up to 1,734,410 options expiring in March 2027. Her remaining beneficial ownership includes 40,513 shares directly and substantial additional indirect holdings in multiple family trusts and by spouse, as described in the footnotes.

Filing Facts

CIK

1082554

Ticker

UTHR

Form

4

Source Type

fda

Accession

0001106578-26-000099

Alert Tier

7